Evaluation of cytisinicline in vaping and e-cigarette users

ORCA-V12020-03-07T19:04:59+00:00
ORCA-1

Achieve has retained the FreeMind Group, an international consulting firm dedicated to assisting life science organizations secure non-dilutive funding to evaluate the potential use of cytisinicline in vapers and e-cigarette users. Achieve and FreeMind will conduct a strategic assessment of potential non-dilutive funding opportunities from various public and private sources, followed by anticipated grant production and submission, to further the clinical development of cytisinicline in this growing population.